Abbott Laboratories (ABT): Price and Financial Metrics

Abbott Laboratories (ABT)

Today's Latest Price: $107.99 USD

2.80 (2.66%)

Updated Sep 30 3:31pm

Add ABT to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ABT Stock Summary

  • Abbott Laboratories's market capitalization of $186,242,050,595 is ahead of 99.19% of US-listed equities.
  • Abbott Laboratories's stock had its IPO on January 1, 1986, making it an older stock than 92.91% of US equities in our set.
  • The volatility of Abbott Laboratories's share price is greater than that of only 7.81% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Abbott Laboratories, a group of peers worth examining would be SAP, SHOP, CCI, CMCSA, and PEP.
  • Visit ABT's SEC page to see the company's official filings. To visit the company's web site, go to
ABT Daily Price Range
ABT 52-Week Price Range

ABT Stock Price Chart Technical Analysis Charts

ABT Price/Volume Stats

Current price $107.99 52-week high $114.19
Prev. close $105.19 52-week low $61.61
Day low $105.74 Volume 5,895,168
Day high $109.48 Avg. volume 7,337,938
50-day MA $103.32 Dividend yield 1.37%
200-day MA $91.58 Market Cap 191.20B

Abbott Laboratories (ABT) Company Bio

Abbott Laboratories manufactures and sells health care products worldwide. The company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The company was founded in 1888 and is based in Abbott Park, Illinois.

ABT Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$107.99$36.2 -66%

Below please find a table outlining a discounted cash flow forecast for ABT, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Abbott Laboratories ranked in the 21th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 65.5%. The most interesting components of our discounted cash flow analysis for Abbott Laboratories ended up being:

  • As a business, ABT is generating more cash flow than 90.99% of positive cash flow stocks in the Healthcare.
  • The business' balance sheet reveals debt to be 9% of the company's capital (with equity being the remaining amount). Approximately merely 21.78% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • ABT's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 38.4% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as ABT, try BAX, BIO, OFIX, REPH, and SRDX.

ABT Latest News Stream

Event/Time News Detail
Loading, please wait...

ABT Latest Social Stream

Loading social stream, please wait...

View Full ABT Social Stream

Latest ABT News From Around the Web

Below are the latest news stories about Abbott Laboratories that investors may wish to consider to help them evaluate ABT as an investment opportunity.

Dividend Aristocrats In The Defensive Sectors

This article provides an update to the article I wrote in March: Since my March article, several changes have been made to the Dividend Aristocrats, and the stock market has mostly recovered from the crash in late February and early March. There are now 65 Dividend Aristocrats and, given growing...

FerdiS on Seeking Alpha | September 29, 2020

Canada agrees to buy almost 8M rapid COVID-19 tests from Abbott

The Canadian government inks an agreement with Abbott ([[ABT]] +0.8%) to purchase 7.9M COVID-19 rapid point-of-care tests, branded as ID NOW, that can generate results from a nasal swab in as little as 13 minutes. The deal is an advance purchase agreement since Health Canada has yet to approve it...

Seeking Alpha | September 29, 2020

Feds announce plan to buy 7.9 million rapid COVID tests

Public Services and Procurement Minister Anita Anand today announced today a plan to buy roughly 7.9 million rapid point-of-care COVID-19 tests from U.S.-based Abbott Laboratories.

CBC News | September 29, 2020

Transplant Diagnostics Market With Current Trends Analysis 2020: Omixon Ltd., CareDx, Affymetrix, Inc, Abbott Laboratories, Inc, Thermo Fisher Scientific, Inc

The Business Research Company offers " Transplant Diagnostics Global Market Report 2020-30: Covid 19 Growth And Change" in its research report store. It is the most comprehensive report available on this market and will help gain a truly global perspective

OpenPR | September 29, 2020

Stress Management Market (Impact of Covid-19) With Top Players like Abbott Laboratories, Eli Lilly and Co., GlaxoSmithKline PLC, Lupin Ltd., Johnson & Johnson Services Inc., Merck & Co. Inc., Pfizer Inc., Fitbit, Azumio, H. Lundbeck A/S

An off-the-shelf report on Stress Management Market which has been compiled after an in-depth analysis of the market trends prevailing across five geographies (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). Various segments of the market such as

OpenPR | September 29, 2020

Read More 'ABT' Stories Here

ABT Price Returns

1-mo -1.35%
3-mo 17.54%
6-mo 37.02%
1-year 34.12%
3-year 113.14%
5-year 188.57%
YTD 25.87%
2019 22.08%
2018 29.06%
2017 52.03%
2016 -12.32%
2015 1.87%

ABT Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full ABT Dividend History

Continue Researching ABT

Here are a few links from around the web to help you further your research on Abbott Laboratories's stock as an investment opportunity:

Abbott Laboratories (ABT) Stock Price | Nasdaq
Abbott Laboratories (ABT) Stock Quote, History and News - Yahoo Finance
Abbott Laboratories (ABT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8297 seconds.